Bilaketaren emaitzak - William C. Gruber

Findu emaitzak
  1. 1
    Prevention of otitis media in children with live attenuated influenza vaccine given intranasally

    Prevention of otitis media in children with live attenuated influenza vaccine given intranasally nork Robert B. Belshe, William C. Gruber

    Argitaratua 2000
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Predicting the Probability for Falls in Community-Dwelling Older Adults

    Predicting the Probability for Falls in Community-Dwelling Older Adults nork Anne Shumway‐Cook, Margaret Baldwin, Nayak L. Polissar, William C. Gruber

    Argitaratua 1997
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Incidence of and Risk Factors for Falls Following Hip Fracture in Community-dwelling Older Adults

    Incidence of and Risk Factors for Falls Following Hip Fracture in Community-dwelling Older Adults nork Anne Shumway‐Cook, Marcia A. Ciol, William C. Gruber, Cynthia A. Robinson

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    The impact of human vaccines on bacterial antimicrobial resistance. A review

    The impact of human vaccines on bacterial antimicrobial resistance. A review nork Kathrin U. Jansen, William C. Gruber, Raphael Simon, James Wassil, Annaliesa S. Anderson

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Comparison of Results of Detection of Rhinovirus by PCR and Viral Culture in Human Nasal Wash Specimens from Subjects with and without Clinical Symptoms of Respiratory Illness

    Comparison of Results of Detection of Rhinovirus by PCR and Viral Culture in Human Nasal Wash Specimens from Subjects with and without Clinical Symptoms of Respiratory Illness nork Peter F. Wright, Anne M. Deatly, Ruth A. Karron, Robert B. Belshe, Jian Shi, William C. Gruber, Yuwei Zhu, Valerie B. Randolph

    Argitaratua 2007
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Illness Severity, Viral Shedding, and Antibody Responses in Infants Hospitalized with Bronchiolitis Caused by Respiratory Syncytial Virus

    Illness Severity, Viral Shedding, and Antibody Responses in Infants Hospitalized with Bronchiolitis Caused by Respiratory Syncytial Virus nork Peter F. Wright, William C. Gruber, M. Robert Peters, George Reed, Yuwei Zhu, F W Robinson, Shanita D. Coleman-Dockery, Barney S. Graham

    Argitaratua 2002
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial

    Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial nork Ron Dagan, Scott D. Patterson, Christine Juergens, David Greenberg, Noga Givon‐Lavi, Nurith Porat, Alejandra Gurtman, William C. Gruber, Daniel A. Scott

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults

    Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults nork Masanari Shiramoto, Ryuzo Hanada, Christine Juergens, Yasuko Shoji, Mizuki Yoshida, Barry Ballan, David Cooper, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children

    Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children nork Humberto Bracco Neto, Calil K. Farhat, Miguel Tregnaghi, Shabir A. Madhi, Ahmad Razmpour, Giuseppe Palladino, Margaret Small, William C. Gruber, Bruce D. Forrest

    Argitaratua 2009
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults

    Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults nork Jose A Suaya, Qin Jiang, Daniel A. Scott, William C. Gruber, Chris Webber, Beate Schmöele-Thoma, Cassandra Hall-Murray, Luis Jódar, Raúl Istúriz

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years

    A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years nork Nicholas Kitchin, Shon Remich, James T. Peterson, Yahong Peng, William C. Gruber, Kathrin U. Jansen, Michael W. Pride, Annaliesa S. Anderson, Charles Knirsch, Chris Webber

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-Nonsusceptible<i>Streptococcus pneumoniae</i>

    Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-Nonsusceptible<i>Streptococcus pne... nork Ron Dagan, Christine Juergens, James Trammel, Scott D. Patterson, David Greenberg, Noga Givon‐Lavi, Nurith Porat, Alejandra Gurtman, William C. Gruber, Daniel A. Scott

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children

    Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children nork Bruce D. Forrest, Michael W. Pride, Andrew J. Dunning, María Rosario Capeding, Tawee Chotpitayasunondh, John S. Tam, Ruth Rappaport, John H. Eldridge, William C. Gruber

    Argitaratua 2008
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)

    A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults) nork Scott D. Patterson, Chris Webber, Michael A. Patton, Wayne Drews, Susanne M. Huijts, Marieke Bolkenbaas, William C. Gruber, Daniel A. Scott, Marc J. M. Bonten

    Argitaratua 2016
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Evaluation of Live Attenuated Influenza Vaccines in Children 6-18 Months of Age: Safety, Immunogenicity, and Efficacy

    Evaluation of Live Attenuated Influenza Vaccines in Children 6-18 Months of Age: Safety, Immunogenicity, and Efficacy nork William C. Gruber, Robert B. Belshe, James C. King, John J. Treanor, Pedro A. Piedra, Peter F. Wright, George Reed, Elizabeth M. Anderson, Frances K. Newman

    Argitaratua 1996
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

    Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada nork Otto G. Vanderkooi, David W. Scheifele, Douglas Girgenti, Scott A. Halperin, Scott D. Patterson, William C. Gruber, Emilio A. Emini, Daniel A. Scott, James D. Kellner

    Argitaratua 2011
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

    The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines nork Peter F. Wright, Ruth A. Karron, Robert B. Belshe, Jian Shi, Valerie B. Randolph, Peter L. Collins, Alice O’Shea, William C. Gruber, Brian R. Murphy

    Argitaratua 2007
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

    Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoi... nork Catherine Cordonnier, Per Ljungman, Christine Juergens, Johan Maertens, Dominik Selleslag, Vani Sundaraiyer, Peter C. Giardina, Keri Clarke, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies

    SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies nork Elizabeth Begier, David Seiden, Michael A. Patton, Edward T. Zito, Joseph M. Severs, David Cooper, Joseph Eiden, William C. Gruber, Kathrin U. Jansen, Annaliesa S. Anderson, Alejandra Gurtman

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine nork Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, Karlis Pauksens, Richard N. Greenberg, Thomas R. Jones, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmöele-Thoma

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: